In The Know-May 2025

May 2025
Pdf Summary
The May 2025 edition of Ed's List highlights several significant contributions to gynecologic oncology literature. A range of studies address diverse topics like the efficacy of different cancer treatments, associations of depression with ovarian cancer risk, trends in cancer incidence, and the prognostic impact of surgical methods and therapies. Here are some key insights:<br /><br />GYN ONC Garage highlights studies, including ones published in JAMA Network Open and JNCI, focusing on racial disparities in cancer antigen levels and cancer risks in BRCA variant carriers. <br /><br />Peripheral blood leukocyte signatures could tease out reliable biomarkers for relapsed ovarian cancer patients' immunotherapy personalization, as found in Mol Oncol.<br /><br />In The Lancet Oncology, a multicenter study uncovers heightened antimicrobial resistance in cancer outpatients, highlighting the need for enhanced infection management.<br /><br />The American Journal of Obstetrics & Gynecology reports that a cancer diagnosis during pregnancy is linked to increased maternal and neonatal morbidity, emphasizing careful management.<br /><br />A JNCI study reveals that one in six patients in Phase 2 cancer trials benefits from treatments that gain FDA approval, presenting a higher therapeutic value than Phase 1 trials.<br /><br />Safety assessments of long-acting contraceptives show an increased breast cancer risk but reduced risks for endometrial and ovarian cancers, equating them to oral contraceptive risks.<br /><br />The impact of depression on ovarian cancer suggests prior depression elevates cancer risk, possibly affecting growth from precursor lesions to invasive carcinoma.<br /><br />A thorough evaluation of clinical trial eligibility in gynecologic cancers suggests that restrictions might limit racial minority participation in trials, despite the need for broader representation.<br /><br />Astudy on the efficacy of chemoradiotherapy versus radiotherapy alone in intermediate-risk cervical cancer suggests a potential for de-escalating treatment due to no notable survival benefit with the addition of chemotherapy.<br /><br />Crucial insights into immunotherapies come from Protein & Cell, revealing how ascites might suppress NK cell function in high-grade serous ovarian cancer by affecting lipid uptake.<br /><br />These findings span mechanisms, treatment efficacies, and patient demographics, collectively aiming to refine and personalize gynecologic cancer management and inform future research.
Keywords
gynecologic oncology
cancer treatments
ovarian cancer
racial disparities
biomarkers
antimicrobial resistance
cancer during pregnancy
clinical trials
chemoradiotherapy
immunotherapy